Cytochrome P-450 gene and drug interaction analysis in patients referred for pharmacogenetic testing

American Journal of Health-System Pharmacy

Volumn 73, Issue 2, 2016, Pages 61-67

  Hocum, Brian Thomas ^a   White, John Raymond ^b   Heck, Jarrod W ^a   Thirumaran, Ranjit K ^a   Moyer, Nicolas ^a   Newman, Richard ^a   Ashcraft, Kristine ^a  

^a Genelex Corporation   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CARVEDILOL; CITALOPRAM; CLOPIDOGREL; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG; HYDROCODONE; ISOENZYME; METOPROLOL; OMEPRAZOLE; OXYCODONE; PARACETAMOL; TRAMADOL; WARFARIN; CYTOCHROME P450;

ADOLESCENT; ADULT; AFRICAN AMERICAN; AGED; ALLELE; ARTICLE; ASIAN; CAUCASIAN; CHILD; DNA POLYMORPHISM; DRUG DRUG GENE INTERACTION; DRUG GENE INTERACTION; DRUG INTERACTION; DRUG METABOLISM; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENETIC ANALYSIS; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HISPANIC; HUMAN; INFANT; JEW; MALE; MULTIRACIAL PERSON; NEWBORN; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VERY ELDERLY; GENETIC POLYMORPHISM; GENETICS; METABOLISM; MIDDLE AGED; PATIENT REFERRAL; PHYSIOLOGY; PRESCHOOL CHILD; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; GENETIC TESTING; HUMANS; INFANT; ISOENZYMES; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, GENETIC; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84962812573     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp150273     Document Type: Article

References (16)

1. Osnabrugge R, Head S, Zijlstra F et al. A systematic review and critical assessment of 11 discordant meta-analyses on reduced-function CYP2C19 genotype and risk of adverse clinical outcomes in clopidogrel users. Genet Med. 2015; 17:3-11.
2. Scott S, Sangkuhl K, Sten C et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013; 94:317-23.
3. Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership. Plavix (clopidogrel bisulfate) prescribing information. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01b14603-8f29-4fa3-8d7e-9d523f802e0b (accessed 2015 Jun 14).
4. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci. 2004; 25:193-200.
5. Karczewski KJ, Daneshjou R, Altman RB. Chapter 7: pharmacogenomics. PLoS Comput Biol. 2012; 8:e1002817.
6. Verbeurgt P, Mamiya T, Oesterheld J. How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping. Pharmacogenomics. 2014; 15:655-65.
7. Genelex Corporation. YouScript. www.youscript.net (accessed 2014 Dec 14).
8. Coleman HC, Oesterheld J, Patterson RD. Genetic data analysis and database tools. U.S. patent 12,031,327. 2012 Jan 17.
9. Patterson RD, Oesterheld J, Coleman HC. Genetic data analysis and database tools. U.S. patent 13,316,144. 2012 Nov 13.
10. Oesterheld J, Patterson RD, Coleman HC. Genetic data analysis and database tools. U.S. patent 13,647,246. 2013 Mar 14.
11. Oesterheld J, Patterson RD, Coleman HC. Genetic data analysis and database tools. U.S. patent 14,163,993. 2014 May 22.
12. Patterson R, Rule D, Coleman H et al. PATH: software to evaluate and improve an algorithm that predicts drug-drug and drug-gene interactions. Poster presented at American Association for Technology in Psychiatry annual meeting. San Francisco, CA; 2009 May 16.
13. Zanger U, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013; 138:103-41.
14. Oldham H, Clarke S. In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol. Drug Metab Dispos. 1997; 25:970-7.
15. Yu B, Chen G, He N et al. Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19. Drug Metab Dispos. 2003; 31:1255-9.
16. Faucette S, Hawke R, Lecluyse E et al. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos. 2000; 28:1222-30.